Convicted of associating with criminals who paid him bribes, and of possessing an arsenal of firearms, the former president ...

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 ...

Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor ...

A new class of cancer drug has been pushed to an almost unimaginable level of potency in the lab, with researchers reporting ...

On December 3, 2025 (local time in Arizona, USA), ImmVira Group ('ImmVira' or the 'Company') announced a poster presentation ...

Health care professionals can have a powerful impact on labeling requirements for drugs by formally petitioning the FDA for ...

Cosmo Pharmaceuticals has revealed topline results from two phase 3 trials which indicate that its topical cream clascoterone ...

Crinetics Pharmaceuticals, Inc. today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble ...

Bangladesh’s economy today is not collapsing; it is undergoing a difficult but necessary reconstruction after more than a ...

Sickle cell disease is associated with chronic oxidative stress, hemolysis, inflammation, and progressive multi--organ injury, including significant cardiopulmonary complications. Mitochondrial ...

U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg ...